首頁 > 市場調查報告書 > 製藥

DDS

市場調查報告書

商品編碼

1442901

無菌注射藥物市場 - 2023-2031 年全球產業分析、規模、佔有率、成長、趨勢與預測

Sterile Injectable Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

出版日期: 2024年01月03日 | 出版商:

Transparency Market Research | 英文 222 Pages | 商品交期: 2-10個工作天內

價格

簡介目錄圖表

無菌注射藥物市場 - 報告範圍

TMR 關於與阿茲海默症相關的全球失智症市場的報告研究了過去以及當前的成長趨勢和機會，以獲得2023 年至2031 年預測期內市場指標的寶貴見解。該報告提供了全球失智症的收入與 2017-2031 年期間阿茲海默症市場相關，考慮 2023 年為基準年，2031 年為預測年。該報告還提供了2023年至2031年全球與阿茲海默症相關的失智症市場的年複合成長率（CAGR %）。

該報告是經過廣泛研究後編寫的。初級研究涉及大部分研究工作，其中分析師對關鍵意見領袖、行業領導者和輿論製造者進行了採訪。二次研究涉及參考主要參與者的產品文獻、年度報告、新聞稿和相關文件，以了解與阿茲海默症相關的失智症市場。

該報告深入研究了與阿茲海默症相關的全球失智症市場的競爭格局。與阿茲海默症相關的全球失智症市場的主要參與者已被確定，並且每一位參與者都已根據各種屬性進行了分析。公司概況、財務狀況、最新發展和 SWOT 是本報告中介紹的全球失智症相關市場參與者的屬性。

介紹
- 主要發現
市場價值預測：按類型，2017-2031
- 小分子
- 大分子
市場吸引力：按類型
市場價值預測：依藥品類別，2017-2031
- 單株抗體 (Mab)
- 細胞因子
- 胰島素
- 胜肽激素
- 疫苗
- 免疫球蛋白
- 血液因素
- 胜肽類抗生素
- 其他
市場吸引力：按藥品類別
市場價值預測：依指標分類，2017-2031
- 心臟病學和代謝紊亂
- 神經病學
- 腫瘤學
- 自體免疫
- 胃腸病學
- 血液學
- 疼痛
- 傳染病
- 其他
市場吸引力：依指標分類
市場價值預測：按配銷通路，2017-2031
- 醫院藥房
- 零售藥房
- 電子商務
市場吸引力：按配銷通路
市場價值預測：依國家/次區域分類，2017-2031
- 海灣合作理事會國家
- 南非
- 中東和非洲其他地區
市場吸引力分析
- 按類型
- 按藥物類別
- 按指示
- 按配銷通路
- 按國家/次區域

第16章：競爭格局

市場參與者 - 競爭矩陣（依公司層級和規模）
市佔率分析：依公司分類（2022 年）
公司簡介
- Baxter International
- Sanofi SA
- Pfizer, Inc.
- GlaxoSmithKline Plc.
- AstraZeneca
- Merck & Co., Inc.
- Novartis AG
- Johnson & Johnson Services, Inc.
- Novo Nordisk A/S
- Gilead Sciences, Inc.

簡介目錄圖表

Product Code: TMRGL34427

Sterile Injectable Drugs Market - Scope of Report

TMR's report on the global dementia associated with Alzheimer's disease market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global dementia associated with Alzheimer's disease market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global dementia associated with Alzheimer's disease market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the dementia associated with Alzheimer's disease market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global dementia associated with Alzheimer's disease market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global dementia associated with Alzheimer's disease market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global dementia associated with Alzheimer's disease market.

The report delves into the competitive landscape of the global dementia associated with Alzheimer's disease market. Key players operating in the global dementia associated with Alzheimer's disease market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global dementia associated with Alzheimer's disease market profiled in this report.

Key Questions Answered in Global dementia associated with Alzheimer's disease Market Report:

What is the sales/revenue generated by dementia associated with Alzheimer's disease across all regions during the forecast period?
What are the opportunities in the global dementia associated with Alzheimer's disease market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2031?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?

Sterile Injectable Drugs Market - Research Objectives and Research Approach

The comprehensive report on the global dementia associated with Alzheimer's disease market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global dementia associated with Alzheimer's disease market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global dementia associated with Alzheimer's disease market.

1. Preface

1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Sterile Injectable Drugs Market

4. Market Overview

4.1. Introduction
- 4.1.1. Type Definition
- 4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
4.4. Global Sterile Injectable Drugs Market Analysis and Forecast, 2017-2031

5. Key Insights

5.1. Pipeline Analysis
5.2. Key Type/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry

6. Global Sterile Injectable Drugs Market Analysis and Forecast, by Type

6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Type, 2017-2031
- 6.3.1. Small Molecule
- 6.3.2. Large Molecule
6.4. Market Attractiveness, by Type

7. Global Sterile Injectable Drugs Market Analysis and Forecast, by Drug Class

7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Drug Class, 2017-2031
- 7.3.1. Monoclonal Antibodies (Mabs)
- 7.3.2. Cytokines
- 7.3.3. Insulin
- 7.3.4. Peptide Hormones
- 7.3.5. Vaccine
- 7.3.6. Immunoglobulins
- 7.3.7. Blood Factors
- 7.3.8. Peptide Antibiotics
- 7.3.9. Others
7.4. Market Attractiveness, by Drug Class

8. Global Sterile Injectable Drugs Market Analysis and Forecast, by Indication

8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Indication, 2017-2031
- 8.3.1. Cardiology & Metabolic Disorders
- 8.3.2. Neurology
- 8.3.3. Oncology
- 8.3.4. Autoimmune
- 8.3.5. Gastroenterology
- 8.3.6. Hematology
- 8.3.7. Pain
- 8.3.8. Infectious Disease
- 8.3.9. Others
8.4. Market Attractiveness, by Indication

9. Global Sterile Injectable Drugs Market Analysis and Forecast, by Distribution Channel

9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Distribution Channel, 2017-2031
- 9.3.1. Hospital Pharmacy
- 9.3.2. Retail Pharmacy
- 9.3.3. E-commerce
9.4. Market Attractiveness, by Distribution Channel

10. Global Sterile Injectable Drugs Market Analysis and Forecast, by Region

10.1. Key Findings
10.2. Market Value Forecast, by Region, 2017-2031
- 10.2.1. North America
- 10.2.2. Europe
- 10.2.3. Asia Pacific
- 10.2.4. Latin America
- 10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region

11. North America Sterile Injectable Drugs Market Analysis and Forecast

11.1. Introduction
- 11.1.1. Key Findings
11.2. Market Value Forecast, by Type, 2017-2031
- 11.2.1. Small Molecule
- 11.2.2. Large Molecule
11.3. Market Attractiveness, by Type
11.4. Market Value Forecast, by Drug Class, 2017-2031
- 11.4.1. Monoclonal Antibodies (Mabs)
- 11.4.2. Cytokines
- 11.4.3. Insulin
- 11.4.4. Peptide Hormones
- 11.4.5. Vaccine
- 11.4.6. Immunoglobulins
- 11.4.7. Blood Factors
- 11.4.8. Peptide Antibiotics
- 11.4.9. Others
11.5. Market Attractiveness, by Drug Class
11.6. Market Value Forecast, by Indication, 2017-2031
- 11.6.1. Cardiology & Metabolic Disorders
- 11.6.2. Neurology
- 11.6.3. Oncology
- 11.6.4. Autoimmune
- 11.6.5. Gastroenterology
- 11.6.6. Hematology
- 11.6.7. Pain
- 11.6.8. Infectious Disease
- 11.6.9. Others
11.7. Market Attractiveness, by Indication
11.8. Market Value Forecast, by Distribution Channel, 2017-2031
- 11.8.1. Hospital Pharmacy
- 11.8.2. Retail Pharmacy
- 11.8.3. E-commerce
11.9. Market Attractiveness, by Distribution Channel
11.10. Market Value Forecast, by Country/Sub-region, 2017-2031
- 11.10.1. U.S.
- 11.10.2. Canada
11.11. Market Attractiveness Analysis
- 11.11.1. By Type
- 11.11.2. By Drug Class
- 11.11.3. By Indication
- 11.11.4. By Distribution Channel
- 11.11.5. By Country

12. Europe Sterile Injectable Drugs Market Analysis and Forecast

12.1. Introduction
- 12.1.1. Key Findings
12.2. Market Value Forecast, by Type, 2017-2031
- 12.2.1. Small Molecule
- 12.2.2. Large Molecule
12.3. Market Attractiveness, by Type
12.4. Market Value Forecast, by Drug Class, 2017-2031
- 12.4.1. Monoclonal Antibodies (Mabs)
- 12.4.2. Cytokines
- 12.4.3. Insulin
- 12.4.4. Peptide Hormones
- 12.4.5. Vaccine
- 12.4.6. Immunoglobulins
- 12.4.7. Blood Factors
- 12.4.8. Peptide Antibiotics
- 12.4.9. Others
12.5. Market Attractiveness, by Drug Class
12.6. Market Value Forecast, by Indication, 2017-2031
- 12.6.1. Cardiology & Metabolic Disorders
- 12.6.2. Neurology
- 12.6.3. Oncology
- 12.6.4. Autoimmune
- 12.6.5. Gastroenterology
- 12.6.6. Hematology
- 12.6.7. Pain
- 12.6.8. Infectious Disease
- 12.6.9. Others
12.7. Market Attractiveness, by Indication
12.8. Market Value Forecast, by Distribution Channel, 2017-2031
- 12.8.1. Hospital Pharmacy
- 12.8.2. Retail Pharmacy
- 12.8.3. E-commerce
12.9. Market Attractiveness, by Distribution Channel
12.10. Market Value Forecast, by Country/Sub-region, 2017-2031
- 12.10.1. Germany
- 12.10.2. U.K.
- 12.10.3. France
- 12.10.4. Italy
- 12.10.5. Spain
- 12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
- 12.11.1. By Type
- 12.11.2. By Drug Class
- 12.11.3. By Indication
- 12.11.4. By Distribution Channel
- 12.11.5. By Country/Sub-region

13. Asia Pacific Sterile Injectable Drugs Market Analysis and Forecast

13.1. Introduction
- 13.1.1. Key Findings
13.2. Market Value Forecast, by Type, 2017-2031
- 13.2.1. Small Molecule
- 13.2.2. Large Molecule
13.3. Market Attractiveness, by Type
13.4. Market Value Forecast, by Drug Class, 2017-2031
- 13.4.1. Monoclonal Antibodies (Mabs)
- 13.4.2. Cytokines
- 13.4.3. Insulin
- 13.4.4. Peptide Hormones
- 13.4.5. Vaccine
- 13.4.6. Immunoglobulins
- 13.4.7. Blood Factors
- 13.4.8. Peptide Antibiotics
- 13.4.9. Others
13.5. Market Attractiveness, by Drug Class
13.6. Market Value Forecast, by Indication, 2017-2031
- 13.6.1. Cardiology & Metabolic Disorders
- 13.6.2. Neurology
- 13.6.3. Oncology
- 13.6.4. Autoimmune
- 13.6.5. Gastroenterology
- 13.6.6. Hematology
- 13.6.7. Pain
- 13.6.8. Infectious Disease
- 13.6.9. Others
13.7. Market Attractiveness, by Indication
13.8. Market Value Forecast, by Distribution Channel, 2017-2031
- 13.8.1. Hospital Pharmacy
- 13.8.2. Retail Pharmacy
- 13.8.3. E-commerce
13.9. Market Attractiveness, by Distribution Channel
13.10. Market Value Forecast, by Country/Sub-region, 2017-2031
- 13.10.1. China
- 13.10.2. Japan
- 13.10.3. India
- 13.10.4. Australia & New Zealand
- 13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
- 13.11.1. By Type
- 13.11.2. By Drug Class
- 13.11.3. By Indication
- 13.11.4. By Distribution Channel
- 13.11.5. By Country/Sub-region

14. Latin America Sterile Injectable Drugs Market Analysis and Forecast

14.1. Introduction
- 14.1.1. Key Findings
14.2. Market Value Forecast, by Type, 2017-2031
- 14.2.1. Small Molecule
- 14.2.2. Large Molecule
14.3. Market Attractiveness, by Type
14.4. Market Value Forecast, by Drug Class, 2017-2031
- 14.4.1. Monoclonal Antibodies (Mabs)
- 14.4.2. Cytokines
- 14.4.3. Insulin
- 14.4.4. Peptide Hormones
- 14.4.5. Vaccine
- 14.4.6. Immunoglobulins
- 14.4.7. Blood Factors
- 14.4.8. Peptide Antibiotics
- 14.4.9. Others
14.5. Market Attractiveness, by Drug Class
14.6. Market Value Forecast, by Indication, 2017-2031
- 14.6.1. Cardiology & Metabolic Disorders
- 14.6.2. Neurology
- 14.6.3. Oncology
- 14.6.4. Autoimmune
- 14.6.5. Gastroenterology
- 14.6.6. Hematology
- 14.6.7. Pain
- 14.6.8. Infectious Disease
- 14.6.9. Others
14.7. Market Attractiveness, by Indication
14.8. Market Value Forecast, by Distribution Channel, 2017-2031
- 14.8.1. Hospital Pharmacy
- 14.8.2. Retail Pharmacy
- 14.8.3. E-commerce
14.9. Market Attractiveness, by Distribution Channel
14.10. Market Value Forecast, by Country/Sub-region, 2017-2031
- 14.10.1. Brazil
- 14.10.2. Mexico
- 14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
- 14.11.1. By Type
- 14.11.2. By Drug Class
- 14.11.3. By Indication
- 14.11.4. By Distribution Channel
- 14.11.5. By Country/Sub-region

15. Middle East & Africa Sterile Injectable Drugs Market ;Analysis and Forecast

15.1. Introduction
- 15.1.1. Key Findings
15.2. Market Value Forecast, by Type, 2017-2031
- 15.2.1. Small Molecule
- 15.2.2. Large Molecule
15.3. Market Attractiveness, by Type
15.4. Market Value Forecast, by Drug Class, 2017-2031
- 15.4.1. Monoclonal Antibodies (Mabs)
- 15.4.2. Cytokines
- 15.4.3. Insulin
- 15.4.4. Peptide Hormones
- 15.4.5. Vaccine
- 15.4.6. Immunoglobulins
- 15.4.7. Blood Factors
- 15.4.8. Peptide Antibiotics
- 15.4.9. Others
15.5. Market Attractiveness, by Drug Class
15.6. Market Value Forecast, by Indication, 2017-2031
- 15.6.1. Cardiology & Metabolic Disorders
- 15.6.2. Neurology
- 15.6.3. Oncology
- 15.6.4. Autoimmune
- 15.6.5. Gastroenterology
- 15.6.6. Hematology
- 15.6.7. Pain
- 15.6.8. Infectious Disease
- 15.6.9. Others
15.7. Market Attractiveness, by Indication
15.8. Market Value Forecast, by Distribution Channel, 2017-2031
- 15.8.1. Hospital Pharmacy
- 15.8.2. Retail Pharmacy
- 15.8.3. E-commerce
15.9. Market Attractiveness, by Distribution Channel
15.10. Market Value Forecast, by Country/Sub-region, 2017-2031
- 15.10.1. GCC Countries
- 15.10.2. South Africa
- 15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
- 15.11.1. By Type
- 15.11.2. By Drug Class
- 15.11.3. By Indication
- 15.11.4. By Distribution Channel
- 15.11.5. By Country/Sub-region

16. Competition Landscape

16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2022)
16.3. Company Profiles
- 16.3.1. Baxter International
  - 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.1.2. Type Portfolio
  - 16.3.1.3. Financial Overview
  - 16.3.1.4. SWOT Analysis
  - 16.3.1.5. Strategic Overview
- 16.3.2. Sanofi S.A
  - 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.2.2. Type Portfolio
  - 16.3.2.3. Financial Overview
  - 16.3.2.4. SWOT Analysis
  - 16.3.2.5. Strategic Overview
- 16.3.3. Pfizer, Inc.
  - 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.3.2. Type Portfolio
  - 16.3.3.3. Financial Overview
  - 16.3.3.4. SWOT Analysis
  - 16.3.3.5. Strategic Overview
- 16.3.4. GlaxoSmithKline Plc.
  - 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.4.2. Type Portfolio
  - 16.3.4.3. Financial Overview
  - 16.3.4.4. SWOT Analysis
  - 16.3.4.5. Strategic Overview
- 16.3.5. AstraZeneca
  - 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.5.2. Type Portfolio
  - 16.3.5.3. Financial Overview
  - 16.3.5.4. SWOT Analysis
  - 16.3.5.5. Strategic Overview
- 16.3.6. Merck & Co., Inc.
  - 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.6.2. Type Portfolio
  - 16.3.6.3. Financial Overview
  - 16.3.6.4. SWOT Analysis
  - 16.3.6.5. Strategic Overview
- 16.3.7. Novartis AG
  - 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.7.2. Type Portfolio
  - 16.3.7.3. Financial Overview
  - 16.3.7.4. SWOT Analysis
  - 16.3.7.5. Strategic Overview
- 16.3.8. Johnson & Johnson Services, Inc.
  - 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.8.2. Type Portfolio
  - 16.3.8.3. Financial Overview
  - 16.3.8.4. SWOT Analysis
  - 16.3.8.5. Strategic Overview
- 16.3.9. Novo Nordisk A/S
  - 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.9.2. Type Portfolio
  - 16.3.9.3. Financial Overview
  - 16.3.9.4. SWOT Analysis
  - 16.3.9.5. Strategic Overview
- 16.3.10. Gilead Sciences, Inc.
  - 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.10.2. Type Portfolio
  - 16.3.10.3. Financial Overview
  - 16.3.10.4. SWOT Analysis
  - 16.3.10.5. Strategic Overview

簡介目錄圖表

List of Tables

Table 01: Global Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Type, 2017-2031
Table 02: Global Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 03: Global Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 04: Global Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031
Table 05: Global Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Region, 2017-2031
Table 06: North America Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Country, 2017-2031
Table 07: North America Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Type, 2017-2031
Table 08: North America Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 09: North America Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031
Table 10: North America Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 11: Europe Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 12: Europe Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Type, 2017-2031
Table 13: Europe Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 14: Europe Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031
Table 15: Europe Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 16: Asia Pacific Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 17: Asia Pacific Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Type, 2017-2031
Table 18: Asia Pacific Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 19: Asia Pacific Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031
Table 20: Asia Pacific Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 21: Latin America Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 22: Latin America Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Type, 2017-2031
Table 23: Latin America Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 24: Latin America Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031
Table 25: Latin America Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 26: Middle East & Africa Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 27: Middle East & Africa Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Type, 2017-2031
Table 28: Middle East & Africa Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 29: Middle East & Africa Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031
Table 30: Middle East & Africa Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031

List of Figures

Figure 01: Global Sterile Injectable Drugs Market Size (US$ Mn), by Region, 2022 and 2031
Figure 02: Global Sterile Injectable Drugs Market Revenue (US$ Mn), by Type, 2022
Figure 03: Global Sterile Injectable Drugs Market Value Share, by Type, 2022
Figure 04: Global Sterile Injectable Drugs Market Revenue (US$ Mn), by Drug Class, 2022
Figure 05: Global Sterile Injectable Drugs Market Value Share, by Drug Class, 2022
Figure 06: Global Sterile Injectable Drugs Market Revenue (US$ Mn), by Indication, 2022
Figure 07: Global Sterile Injectable Drugs Market Value Share, by Indication, 2022
Figure 08: Global Sterile Injectable Drugs Market Revenue (US$ Mn), by Distribution Channel, 2022
Figure 09: Global Sterile Injectable Drugs Market Value Share, by Distribution Channel, 2022
Figure 10: Global Sterile Injectable Drugs Market Value Share, by Region, 2022
Figure 11: Global Sterile Injectable Drugs Market Value (US$ Mn) Forecast, 2017-2031
Figure 12: Global Sterile Injectable Drugs Market Value Share Analysis, by Type, 2022 and 2031
Figure 13: Global Sterile Injectable Drugs Market Attractiveness Analysis, by Type, 2023-2031
Figure 14: Global Sterile Injectable Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 15: Global Sterile Injectable Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 16: Global Sterile Injectable Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 17: Global Sterile Injectable Drugs Market Attractiveness Analysis, by Indication, 2023-2031
Figure 18: Global Sterile Injectable Drugs Market Revenue (US$ Mn), by Distribution Channel, 2022
Figure 19: Global Sterile Injectable Drugs Market Value Share, by Distribution Channel, 2022
Figure 20: Global Sterile Injectable Drugs Market Value Share Analysis, by Region, 2022 and 2031
Figure 21: Global Sterile Injectable Drugs Market Attractiveness Analysis, by Region, 2023-2031
Figure 22: North America Sterile Injectable Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 23: North America Sterile Injectable Drugs Market Attractiveness Analysis, by Country, 2023-2031
Figure 24: North America Sterile Injectable Drugs Market Value Share Analysis, by Country, 2022 and 2031
Figure 25: North America Sterile Injectable Drugs Market Value Share Analysis, by Type, 2022 and 2031
Figure 26: North America Sterile Injectable Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 27: North America Sterile Injectable Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 28: North America Sterile Injectable Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 29: North America Sterile Injectable Drugs Market Attractiveness Analysis, by Type, 2023-2031
Figure 30: North America Sterile Injectable Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 31: North America Sterile Injectable Drugs Market Attractiveness Analysis, by Indication, 2023-2031
Figure 32: North America Sterile Injectable Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 33: Europe Sterile Injectable Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 34: Europe Sterile Injectable Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 35: Europe Sterile Injectable Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 36: Europe Sterile Injectable Drugs Market Value Share Analysis, by Type, 2022 and 2031
Figure 37: Europe Sterile Injectable Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 38: Europe Sterile Injectable Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 39: Europe Sterile Injectable Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 40: Europe Sterile Injectable Drugs Market Attractiveness Analysis, by Type, 2023-2031
Figure 41: Europe Sterile Injectable Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 42: Europe Sterile Injectable Drugs Market Attractiveness Analysis, by Indication, 2023-2031
Figure 43: Europe Sterile Injectable Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 44: Asia Pacific Sterile Injectable Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 45: Asia Pacific Sterile Injectable Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 46: Asia Pacific Sterile Injectable Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 47: Asia Pacific Sterile Injectable Drugs Market Value Share Analysis, by Type, 2022 and 2031
Figure 48: Asia Pacific Sterile Injectable Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 49: Asia Pacific Sterile Injectable Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 50: Asia Pacific Sterile Injectable Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 51: Asia Pacific Sterile Injectable Drugs Market Attractiveness Analysis, by Type, 2023-2031
Figure 52: Asia Pacific Sterile Injectable Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 53: Asia Pacific Sterile Injectable Drugs Market Attractiveness Analysis, by Indication, 2023-2031
Figure 54: Asia Pacific Sterile Injectable Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
Figure 55: Latin America Sterile Injectable Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 56: Latin America Sterile Injectable Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 57: Latin America Sterile Injectable Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 58: Latin America Sterile Injectable Drugs Market Value Share Analysis, by Type, 2022 and 2031
Figure 59: Latin America Sterile Injectable Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 60: Latin America Sterile Injectable Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 61: Latin America Sterile Injectable Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 62: Latin America Sterile Injectable Drugs Market Attractiveness Analysis, by Type, 2023-2031
Figure 63: Latin America Sterile Injectable Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 64: Latin America Sterile Injectable Drugs Market Attractiveness Analysis, by Indication, 2023-2031
Figure 65: Latin America Sterile Injectable Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 66: Middle East & Africa Sterile Injectable Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 67: Middle East & Africa Sterile Injectable Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 68: Middle East & Africa Sterile Injectable Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 69: Middle East & Africa Sterile Injectable Drugs Market Value Share Analysis, by Type, 2022 and 2031
Figure 70: Middle East & Africa Sterile Injectable Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 71: Middle East & Africa Sterile Injectable Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 72: Middle East & Africa Sterile Injectable Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 73: Middle East & Africa Sterile Injectable Drugs Market Attractiveness Analysis, by Type, 2023-2031
Figure 74: Middle East & Africa Sterile Injectable Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 75: Middle East & Africa Sterile Injectable Drugs Market Attractiveness Analysis, by Indication, 2023-2031
Figure 76: Middle East & Africa Sterile Injectable Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031